Article Swipe

PDF

Nicoletta Libera Lilli , Delphine Révy , Sandra Robelet , Béatrice Lejeune ·

YOU? · · 2019 · Open Access · · DOI: https://doi.org/10.2147/dnnd.s202966

Our results demonstrate the in vitro efficacy of MIM on two essential mechanisms of PD and propose the MI approach as a new ally in the regulation of neuroinflammation and in the treatment of this degenerative disease.

Related Topics

Concepts

Oxidative stress Dopaminergic Parkinson's disease Medicine In vitro Pharmacology Neuroprotection Rat model Neuroscience Chemistry Dopamine Biology Internal medicine Biochemistry Disease

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.2147/dnnd.s202966
PDF: https://www.dovepress.com/getfile.php?fileID=51020
OA Status: diamond
Cited By: 10
References: 54
Related Works: 10
OpenAlex ID: https://openalex.org/W2954723822

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W2954723822

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.2147/dnnd.s202966

Digital Object Identifier
Title: <p>Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease</p>

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2019

Year of publication
Publication date: 2019-07-01

Full publication date if available
Authors: Nicoletta Libera Lilli, Delphine Révy, Sandra Robelet, Béatrice Lejeune

List of authors in order
Landing page: https://doi.org/10.2147/dnnd.s202966

Publisher landing page
PDF URL: https://www.dovepress.com/getfile.php?fileID=51020

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: diamond

Open access status per OpenAlex
OA URL: https://www.dovepress.com/getfile.php?fileID=51020

Direct OA link when available
Concepts: Oxidative stress, Dopaminergic, Parkinson's disease, Medicine, In vitro, Pharmacology, Neuroprotection, Rat model, Neuroscience, Chemistry, Dopamine, Biology, Internal medicine, Biochemistry, Disease

Top concepts (fields/topics) attached by OpenAlex
Cited by: 10

Total citation count in OpenAlex
Citations by year (recent): 2024: 1, 2022: 2, 2021: 3, 2020: 3, 2019: 1

Per-year citation counts (last 5 years)
References (count): 54

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W2954723822
doi	https://doi.org/10.2147/dnnd.s202966
ids.doi	https://doi.org/10.2147/dnnd.s202966
ids.mag	2954723822
ids.pmid	https://pubmed.ncbi.nlm.nih.gov/31372089
ids.openalex	https://openalex.org/W2954723822
fwci	1.7405641
type	article
title	<p>Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease</p>
biblio.issue
biblio.volume	Volume 9
biblio.last_page	88
biblio.first_page	79
topics[0].id	https://openalex.org/T10085
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9997000098228455
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2728
topics[0].subfield.display_name	Neurology
topics[0].display_name	Parkinson's Disease Mechanisms and Treatments
topics[1].id	https://openalex.org/T10483
topics[1].field.id	https://openalex.org/fields/28
topics[1].field.display_name	Neuroscience
topics[1].score	0.9951000213623047
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/2804
topics[1].subfield.display_name	Cellular and Molecular Neuroscience
topics[1].display_name	Nerve injury and regeneration
topics[2].id	https://openalex.org/T11601
topics[2].field.id	https://openalex.org/fields/28
topics[2].field.display_name	Neuroscience
topics[2].score	0.9787999987602234
topics[2].domain.id	https://openalex.org/domains/1
topics[2].domain.display_name	Life Sciences
topics[2].subfield.id	https://openalex.org/subfields/2804
topics[2].subfield.display_name	Cellular and Molecular Neuroscience
topics[2].display_name	Neuroscience and Neural Engineering
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2776151105
concepts[0].level	2
concepts[0].score	0.7380011677742004
concepts[0].wikidata	https://www.wikidata.org/wiki/Q898814
concepts[0].display_name	Oxidative stress
concepts[1].id	https://openalex.org/C137183658
concepts[1].level	3
concepts[1].score	0.6914639472961426
concepts[1].wikidata	https://www.wikidata.org/wiki/Q461076
concepts[1].display_name	Dopaminergic
concepts[2].id	https://openalex.org/C2779734285
concepts[2].level	3
concepts[2].score	0.6207121014595032
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11085
concepts[2].display_name	Parkinson's disease
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.520444929599762
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C202751555
concepts[4].level	2
concepts[4].score	0.5007708072662354
concepts[4].wikidata	https://www.wikidata.org/wiki/Q221681
concepts[4].display_name	In vitro
concepts[5].id	https://openalex.org/C98274493
concepts[5].level	1
concepts[5].score	0.47227227687835693
concepts[5].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[5].display_name	Pharmacology
concepts[6].id	https://openalex.org/C25498285
concepts[6].level	2
concepts[6].score	0.4353756010532379
concepts[6].wikidata	https://www.wikidata.org/wiki/Q1981368
concepts[6].display_name	Neuroprotection
concepts[7].id	https://openalex.org/C3019114686
concepts[7].level	2
concepts[7].score	0.41382643580436707
concepts[7].wikidata	https://www.wikidata.org/wiki/Q3089676
concepts[7].display_name	Rat model
concepts[8].id	https://openalex.org/C169760540
concepts[8].level	1
concepts[8].score	0.36866295337677
concepts[8].wikidata	https://www.wikidata.org/wiki/Q207011
concepts[8].display_name	Neuroscience
concepts[9].id	https://openalex.org/C185592680
concepts[9].level	0
concepts[9].score	0.3286464214324951
concepts[9].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[9].display_name	Chemistry
concepts[10].id	https://openalex.org/C513476851
concepts[10].level	2
concepts[10].score	0.2845832109451294
concepts[10].wikidata	https://www.wikidata.org/wiki/Q170304
concepts[10].display_name	Dopamine
concepts[11].id	https://openalex.org/C86803240
concepts[11].level	0
concepts[11].score	0.19735679030418396
concepts[11].wikidata	https://www.wikidata.org/wiki/Q420
concepts[11].display_name	Biology
concepts[12].id	https://openalex.org/C126322002
concepts[12].level	1
concepts[12].score	0.18089523911476135
concepts[12].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[12].display_name	Internal medicine
concepts[13].id	https://openalex.org/C55493867
concepts[13].level	1
concepts[13].score	0.07611000537872314
concepts[13].wikidata	https://www.wikidata.org/wiki/Q7094
concepts[13].display_name	Biochemistry
concepts[14].id	https://openalex.org/C2779134260
concepts[14].level	2
concepts[14].score	0.05699276924133301
concepts[14].wikidata	https://www.wikidata.org/wiki/Q12136
concepts[14].display_name	Disease
keywords[0].id	https://openalex.org/keywords/oxidative-stress
keywords[0].score	0.7380011677742004
keywords[0].display_name	Oxidative stress
keywords[1].id	https://openalex.org/keywords/dopaminergic
keywords[1].score	0.6914639472961426
keywords[1].display_name	Dopaminergic
keywords[2].id	https://openalex.org/keywords/parkinsons-disease
keywords[2].score	0.6207121014595032
keywords[2].display_name	Parkinson's disease
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.520444929599762
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/in-vitro
keywords[4].score	0.5007708072662354
keywords[4].display_name	In vitro
keywords[5].id	https://openalex.org/keywords/pharmacology
keywords[5].score	0.47227227687835693
keywords[5].display_name	Pharmacology
keywords[6].id	https://openalex.org/keywords/neuroprotection
keywords[6].score	0.4353756010532379
keywords[6].display_name	Neuroprotection
keywords[7].id	https://openalex.org/keywords/rat-model
keywords[7].score	0.41382643580436707
keywords[7].display_name	Rat model
keywords[8].id	https://openalex.org/keywords/neuroscience
keywords[8].score	0.36866295337677
keywords[8].display_name	Neuroscience
keywords[9].id	https://openalex.org/keywords/chemistry
keywords[9].score	0.3286464214324951
keywords[9].display_name	Chemistry
keywords[10].id	https://openalex.org/keywords/dopamine
keywords[10].score	0.2845832109451294
keywords[10].display_name	Dopamine
keywords[11].id	https://openalex.org/keywords/biology
keywords[11].score	0.19735679030418396
keywords[11].display_name	Biology
keywords[12].id	https://openalex.org/keywords/internal-medicine
keywords[12].score	0.18089523911476135
keywords[12].display_name	Internal medicine
keywords[13].id	https://openalex.org/keywords/biochemistry
keywords[13].score	0.07611000537872314
keywords[13].display_name	Biochemistry
keywords[14].id	https://openalex.org/keywords/disease
keywords[14].score	0.05699276924133301
keywords[14].display_name	Disease
language	en
locations[0].id	doi:10.2147/dnnd.s202966
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4210190832
locations[0].source.issn	1179-9900
locations[0].source.type	journal
locations[0].source.is_oa	True
locations[0].source.issn_l	1179-9900
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Degenerative Neurological and Neuromuscular Disease
locations[0].source.host_organization	https://openalex.org/P4310320348
locations[0].source.host_organization_name	Dove Medical Press
locations[0].source.host_organization_lineage	https://openalex.org/P4310320348
locations[0].license	cc-by-nc
locations[0].pdf_url	https://www.dovepress.com/getfile.php?fileID=51020
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Degenerative Neurological and Neuromuscular Disease
locations[0].landing_page_url	https://doi.org/10.2147/dnnd.s202966
locations[1].id	pmid:31372089
locations[1].is_oa	False
locations[1].source.id	https://openalex.org/S4306525036
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	PubMed
locations[1].source.host_organization	https://openalex.org/I1299303238
locations[1].source.host_organization_name	National Institutes of Health
locations[1].source.host_organization_lineage	https://openalex.org/I1299303238
locations[1].license
locations[1].pdf_url
locations[1].version	publishedVersion
locations[1].raw_type
locations[1].license_id
locations[1].is_accepted	True
locations[1].is_published	True
locations[1].raw_source_name	Degenerative neurological and neuromuscular disease
locations[1].landing_page_url	https://pubmed.ncbi.nlm.nih.gov/31372089
locations[2].id	pmh:oai:pubmedcentral.nih.gov:6635836
locations[2].is_oa	True
locations[2].source.id	https://openalex.org/S2764455111
locations[2].source.issn
locations[2].source.type	repository
locations[2].source.is_oa	False
locations[2].source.issn_l
locations[2].source.is_core	False
locations[2].source.is_in_doaj	False
locations[2].source.display_name	PubMed Central
locations[2].source.host_organization	https://openalex.org/I1299303238
locations[2].source.host_organization_name	National Institutes of Health
locations[2].source.host_organization_lineage	https://openalex.org/I1299303238
locations[2].license
locations[2].pdf_url
locations[2].version	submittedVersion
locations[2].raw_type	Text
locations[2].license_id
locations[2].is_accepted	False
locations[2].is_published	False
locations[2].raw_source_name	Degener Neurol Neuromuscul Dis
locations[2].landing_page_url	https://www.ncbi.nlm.nih.gov/pmc/articles/6635836
indexed_in	crossref, pubmed
authorships[0].author.id	https://openalex.org/A5059223137
authorships[0].author.orcid	https://orcid.org/0000-0003-1606-4191
authorships[0].author.display_name	Nicoletta Libera Lilli
authorships[0].affiliations[0].raw_affiliation_string	Clinical Affairs, Labo'Life France, Moutiers-Sous-Chantemerle, F-79320, France
authorships[0].author_position	first
authorships[0].raw_author_name	Nicoletta L. Lilli
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Clinical Affairs, Labo'Life France, Moutiers-Sous-Chantemerle, F-79320, France
authorships[1].author.id	https://openalex.org/A5049082678
authorships[1].author.orcid
authorships[1].author.display_name	Delphine Révy
authorships[1].affiliations[0].raw_affiliation_string	Syncrosome, Campus Luminy – Luminy Entreprises, Marseille 13288, France
authorships[1].author_position	middle
authorships[1].raw_author_name	Delphine Révy
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Syncrosome, Campus Luminy – Luminy Entreprises, Marseille 13288, France
authorships[2].author.id	https://openalex.org/A5061825248
authorships[2].author.orcid
authorships[2].author.display_name	Sandra Robelet
authorships[2].affiliations[0].raw_affiliation_string	Syncrosome, Campus Luminy – Luminy Entreprises, Marseille 13288, France
authorships[2].author_position	middle
authorships[2].raw_author_name	Sandra Robelet
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Syncrosome, Campus Luminy – Luminy Entreprises, Marseille 13288, France
authorships[3].author.id	https://openalex.org/A5085089072
authorships[3].author.orcid	https://orcid.org/0000-0001-9067-6116
authorships[3].author.display_name	Béatrice Lejeune
authorships[3].affiliations[0].raw_affiliation_string	Labo'Life Belgium, Parc Scientifique CREALYS, Gembloux 5032, Belgium
authorships[3].author_position	last
authorships[3].raw_author_name	Béatrice Lejeune
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Labo'Life Belgium, Parc Scientifique CREALYS, Gembloux 5032, Belgium
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://www.dovepress.com/getfile.php?fileID=51020
open_access.oa_status	diamond
open_access.any_repository_has_fulltext	False
created_date	2019-07-12T00:00:00
display_name	<p>Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease</p>
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10085
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9997000098228455
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2728
primary_topic.subfield.display_name	Neurology
primary_topic.display_name	Parkinson's Disease Mechanisms and Treatments
related_works	https://openalex.org/W2077655479, https://openalex.org/W2095198015, https://openalex.org/W2995727304, https://openalex.org/W1517805603, https://openalex.org/W123747276, https://openalex.org/W2481738341, https://openalex.org/W3119178414, https://openalex.org/W4401931767, https://openalex.org/W4407819105, https://openalex.org/W2370554327
cited_by_count	10
counts_by_year[0].year	2024
counts_by_year[0].cited_by_count	1
counts_by_year[1].year	2022
counts_by_year[1].cited_by_count	2
counts_by_year[2].year	2021
counts_by_year[2].cited_by_count	3
counts_by_year[3].year	2020
counts_by_year[3].cited_by_count	3
counts_by_year[4].year	2019
counts_by_year[4].cited_by_count	1
locations_count	3
best_oa_location.id	doi:10.2147/dnnd.s202966
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4210190832
best_oa_location.source.issn	1179-9900
best_oa_location.source.type	journal
best_oa_location.source.is_oa	True
best_oa_location.source.issn_l	1179-9900
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Degenerative Neurological and Neuromuscular Disease
best_oa_location.source.host_organization	https://openalex.org/P4310320348
best_oa_location.source.host_organization_name	Dove Medical Press
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320348
best_oa_location.license	cc-by-nc
best_oa_location.pdf_url	https://www.dovepress.com/getfile.php?fileID=51020
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Degenerative Neurological and Neuromuscular Disease
best_oa_location.landing_page_url	https://doi.org/10.2147/dnnd.s202966
primary_location.id	doi:10.2147/dnnd.s202966
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4210190832
primary_location.source.issn	1179-9900
primary_location.source.type	journal
primary_location.source.is_oa	True
primary_location.source.issn_l	1179-9900
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Degenerative Neurological and Neuromuscular Disease
primary_location.source.host_organization	https://openalex.org/P4310320348
primary_location.source.host_organization_name	Dove Medical Press
primary_location.source.host_organization_lineage	https://openalex.org/P4310320348
primary_location.license	cc-by-nc
primary_location.pdf_url	https://www.dovepress.com/getfile.php?fileID=51020
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Degenerative Neurological and Neuromuscular Disease
primary_location.landing_page_url	https://doi.org/10.2147/dnnd.s202966
publication_date	2019-07-01
publication_year	2019
referenced_works	https://openalex.org/W2053368008, https://openalex.org/W2625202770, https://openalex.org/W2090377912, https://openalex.org/W4200558553, https://openalex.org/W2000293969, https://openalex.org/W6646415611, https://openalex.org/W2138578148, https://openalex.org/W2052122668, https://openalex.org/W2027603848, https://openalex.org/W1973174174, https://openalex.org/W2075074709, https://openalex.org/W2299440077, https://openalex.org/W2065000444, https://openalex.org/W2011277388, https://openalex.org/W2424850491, https://openalex.org/W2153244109, https://openalex.org/W2531872507, https://openalex.org/W2605634801, https://openalex.org/W2586065799, https://openalex.org/W1979205386, https://openalex.org/W1965134160, https://openalex.org/W1590012920, https://openalex.org/W2093421538, https://openalex.org/W2109532136, https://openalex.org/W1642086117, https://openalex.org/W2083702527, https://openalex.org/W1994452959, https://openalex.org/W2104291580, https://openalex.org/W3024060052, https://openalex.org/W2063640110, https://openalex.org/W1969291345, https://openalex.org/W2050686031, https://openalex.org/W2014754503, https://openalex.org/W2040705927, https://openalex.org/W2019354053, https://openalex.org/W1515497590, https://openalex.org/W2091995999, https://openalex.org/W2564137349, https://openalex.org/W2107129978, https://openalex.org/W2041463273, https://openalex.org/W2123012822, https://openalex.org/W2412966736, https://openalex.org/W2781234735, https://openalex.org/W2078034476, https://openalex.org/W220741418, https://openalex.org/W1519604321, https://openalex.org/W2057286215, https://openalex.org/W1980800373, https://openalex.org/W2091789499, https://openalex.org/W1983019829, https://openalex.org/W4232337397, https://openalex.org/W2143906078, https://openalex.org/W2068423530, https://openalex.org/W2051768564
referenced_works_count	54
abstract_inverted_index.a	21
abstract_inverted_index.MI	18
abstract_inverted_index.PD	14
abstract_inverted_index.as	20
abstract_inverted_index.in	4, 24, 30
abstract_inverted_index.of	7, 13, 27, 33
abstract_inverted_index.on	9
abstract_inverted_index.MIM	8
abstract_inverted_index.Our	0
abstract_inverted_index.and	15, 29
abstract_inverted_index.new	22
abstract_inverted_index.the	3, 17, 25, 31
abstract_inverted_index.two	10
abstract_inverted_index.ally	23
abstract_inverted_index.this	34
abstract_inverted_index.vitro	5
abstract_inverted_index.propose	16
abstract_inverted_index.results	1
abstract_inverted_index.approach	19
abstract_inverted_index.disease.	36
abstract_inverted_index.efficacy	6
abstract_inverted_index.essential	11
abstract_inverted_index.treatment	32
abstract_inverted_index.mechanisms	12
abstract_inverted_index.regulation	26
abstract_inverted_index.demonstrate	2
abstract_inverted_index.degenerative	35
abstract_inverted_index.neuroinflammation	28
cited_by_percentile_year.max	97
cited_by_percentile_year.min	90
countries_distinct_count	0
institutions_distinct_count	4
citation_normalized_percentile.value	0.80697301
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False